Latest Insider Transactions at Gilead Sciences, Inc. (GILD)
This section provides a real-time view of insider transactions for Gilead Sciences, Inc. (GILD). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of GILEAD SCIENCES, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of GILEAD SCIENCES, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 06
2021
|
Andrew D Dickinson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,818
+5.21%
|
-
|
Feb 06
2021
|
Brett A Pletcher EVP,Corp Affairs & Gen Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
753
-2.39%
|
$51,204
$68.46 P/Share
|
Feb 06
2021
|
Brett A Pletcher EVP,Corp Affairs & Gen Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,728
+7.96%
|
-
|
Feb 06
2021
|
Diane E. Wilfong SVP, Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
533
-3.07%
|
$36,244
$68.46 P/Share
|
Feb 06
2021
|
Diane E. Wilfong SVP, Controller & CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,866
+9.71%
|
-
|
Feb 01
2021
|
Brett A Pletcher EVP,Corp Affairs & Gen Counsel |
SELL
Open market or private sale
|
Direct |
9,711
-25.2%
|
$631,215
$65.97 P/Share
|
Jan 28
2021
|
Sandra Horning Director |
BUY
Exercise of conversion of derivative security
|
Direct |
632
+50.0%
|
-
|
Jan 26
2021
|
Andrew D Dickinson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
878
-2.73%
|
$57,948
$66.7 P/Share
|
Jan 26
2021
|
Andrew D Dickinson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,855
+19.52%
|
-
|
Jan 26
2021
|
Daniel Patrick O'Day Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
59,100
+35.65%
|
-
|
Jan 26
2021
|
Merdad Parsey Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,214
+43.64%
|
-
|
Jan 26
2021
|
Johanna Mercier Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,068
+23.7%
|
-
|
Jan 26
2021
|
Diane E. Wilfong SVP, Controller & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
1,294
+7.71%
|
-
|
Jan 26
2021
|
Brett A Pletcher EVP,Corp Affairs & Gen Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,736
-8.84%
|
$246,576
$66.7 P/Share
|
Jan 26
2021
|
Brett A Pletcher EVP,Corp Affairs & Gen Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
27,635
+28.56%
|
-
|
Jan 22
2021
|
Kevin E Lofton Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,282
+21.47%
|
$405,640
$20.64 P/Share
|
Nov 23
2020
|
Kevin E Lofton Director |
SELL
Bona fide gift
|
Direct |
21,720
-28.71%
|
-
|
Nov 10
2020
|
Diane E. Wilfong SVP, Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
611
-4.13%
|
$36,660
$60.62 P/Share
|
Nov 10
2020
|
Diane E. Wilfong SVP, Controller & CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,430
+4.71%
|
-
|
Nov 10
2020
|
Merdad Parsey Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,416
-47.36%
|
$144,960
$60.62 P/Share
|
Nov 10
2020
|
Merdad Parsey Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,101
+50.0%
|
-
|
Nov 10
2020
|
Andrew D Dickinson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,399
-7.91%
|
$83,940
$60.62 P/Share
|
Nov 10
2020
|
Andrew D Dickinson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,046
+8.23%
|
-
|
Nov 03
2020
|
Johanna Mercier Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,282
-40.69%
|
$712,356
$58.83 P/Share
|
Nov 03
2020
|
Johanna Mercier Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,270
+46.53%
|
-
|
Oct 01
2020
|
Richard James Whitley Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,434
+4.4%
|
-
|